Concert Bio Ltd. is a specialized biotechnology company focused on the translation and innovation of complex biological systems. Founded in 2021, the company operates from its Translation & Innovation Hub (I-Hub) located in London, UK, with a registered number of 13568883. Concert Bio’s primary service area centers on the development of novel technologies and solutions for pharmaceutical and diagnostic applications. The company’s core competencies lie in utilizing advanced molecular biology techniques, including CRISPR-based gene editing and synthetic biology, to create customized biological tools and assays. Concert Bio specializes in targeted protein engineering and the design of novel biological pathways. Currently, Concert Bio is active and maintains a strong international presence, with strategic partnerships and collaborations across Europe and North America. The company’s size estimate is currently considered small, with a focus on research and development. Concert Bio’s key focus is on translating fundamental scientific discoveries into commercially viable products. The company is a Skilled Worker, holding a Worker (A) rating, and is actively seeking to expand its international team through hiring indicators. SIC codes include: - 72110: Research and experimental development on biotechnology, - 6311: Biotechnology, - 6311: Pharmaceutical intermediates.

Concert Bio Ltd. is a specialized biotechnology company focused on the translation and innovation of complex biological systems. Founded in 2021, the company operates from its Translation & Innovation Hub (I-Hub) located in London, UK, with a registered number of 13568883. Concert Bio’s primary service area centers on the development of novel technologies and solutions for pharmaceutical and diagnostic applications. The company’s core competencies lie in utilizing advanced molecular biology techniques, including CRISPR-based gene editing and synthetic biology, to create customized biological tools and assays. Concert Bio specializes in targeted protein engineering and the design of novel biological pathways. Currently, Concert Bio is active and maintains a strong international presence, with strategic partnerships and collaborations across Europe and North America. The company’s size estimate is currently considered small, with a focus on research and development. Concert Bio’s key focus is on translating fundamental scientific discoveries into commercially viable products. The company is a Skilled Worker, holding a Worker (A) rating, and is actively seeking to expand its international team through hiring indicators. SIC codes include: - 72110: Research and experimental development on biotechnology, - 6311: Biotechnology, - 6311: Pharmaceutical intermediates.